Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Pedro Such"'
Autor:
Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham, Na Jin, Suzanne Watkin, Zhen Zhang, Frank Larsen, Matthew Harlin
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 14 (2024)
The purpose of this summary is to explain key findings from a study that included people with schizophrenia, as described in two separate articles (see the ‘Further Information’ section for more details). The study compared a new formulation of a
Externí odkaz:
https://doaj.org/article/5c1eb0c0106247059191289ddd1b31ed
Autor:
Roger S. McIntyre, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Na Jin, Suzanne Watkin, Zhen Zhang, Frank Larsen, Matthew Harlin
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 14 (2024)
The purpose of this summary is to explain key findings from a study that included people with bipolar I disorder, as described in two separate articles (see the ‘Further Information’ section for more details). The study compared a new formulation
Externí odkaz:
https://doaj.org/article/8488187a75154f3f9759df68707e2db3
Autor:
Joseph R. Calabrese, Na Jin, Brian Johnson, Pedro Such, Ross A. Baker, Jessica Madera, Peter Hertel, Jocelyn Ottinger, Joan Amatniek, Hiroaki Kawasaki
Publikováno v:
International Journal of Bipolar Disorders, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Background The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability,
Externí odkaz:
https://doaj.org/article/21408d497c3b417693fa2e3361884e5b
Autor:
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larsen
Publikováno v:
CNS Drugs. 37:337-350
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d317b45a88f1e040068af542be2aa82
https://doi.org/10.1007/s40263-023-00996-8
https://doi.org/10.1007/s40263-023-00996-8
Autor:
John M, Kane, Bruce J, Kinon, Carlos, Forray, Pedro, Such, Aurélia, Mittoux, Ole M, Lemming, Peter, Hertel, Oliver D, Howes
Publikováno v:
Schizophrenia Research. 248:271-278
Treatment resistance constitutes the highest burden of disease within schizophrenia. We hypothesized that the synergistic activity of Lu AF35700 at dopamine Dsub1/suband Dsub2/subreceptors might provide superior antipsychotic effects versus first-lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0294ced9345eb3d29be0e89f9e7dbc8
https://doi.org/10.1016/j.schres.2022.09.012
https://doi.org/10.1016/j.schres.2022.09.012
Autor:
Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, Christoph von der Goltz
Publikováno v:
European Neuropsychopharmacology. 61:4-14
Lu AF11167 is a selective, high-affinity inhibitor of PDE10A that modulates dopamine D1 and D2 receptor-mediated intraneuronal signalling without binding to these receptors. This randomized, double-blind, parallel-group, placebo-controlled study (NCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9036d76b0caa39f7ff24e4674388370
https://doi.org/10.1016/j.euroneuro.2022.05.009
https://doi.org/10.1016/j.euroneuro.2022.05.009
Autor:
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Frank Larsen
Publikováno v:
CNS Spectrums. 28:237-238
IntroductionAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, intended for the treatment of schizophrenia and maintenance monotherapy tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a37462e35d2125fef43d89ff0b1a22eb
https://doi.org/10.1017/s1092852923001670
https://doi.org/10.1017/s1092852923001670
Safety And Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg in Adult Patients With Schizophrenia
Publikováno v:
CNS Spectrums. 28:242-243
BackgroundAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::548df845274ad515f56fb692306c927d
https://doi.org/10.1017/s109285292300175x
https://doi.org/10.1017/s109285292300175x
Publikováno v:
CNS Spectrums. 28:256-256
IntroductionAntipsychotic treatment can help improve outcomes in schizophrenia by reducing the risk of relapse and psychiatric hospitalization, and increasing rates of remission and recovery, particularly when used early in the disease course. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5387e2ec0df84f286e8834a6a3e88dc2
https://doi.org/10.1017/s1092852923002018
https://doi.org/10.1017/s1092852923002018
Publikováno v:
CNS Spectrums. 28:244-244
BackgroundAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5afbeca3037862681be7d66cb74f6d12
https://doi.org/10.1017/s1092852923001785
https://doi.org/10.1017/s1092852923001785